These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12807687)

  • 1. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review.
    Hightower M; Kallas EG
    Braz J Infect Dis; 2003 Feb; 7(1):7-15. PubMed ID: 12807687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
    Bhana N; Ormrod D; Perry CM; Figgitt DP
    Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
    Wintergerst U; Hoffmann F; Sölder B; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH
    Pediatr Infect Dis J; 1998 Jun; 17(6):495-9. PubMed ID: 9655541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of mutations that confer resistance to nucleoside analogs and protease inhibitors in HIV-1-infected patients. Study Group on Resistance to Antiretroviral Agents].
    Martínez G; Sarría L; Campelo C; Merchán A; Cisterna R
    Rev Esp Quimioter; 1999 Dec; 12(4):317-24. PubMed ID: 10855010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV/AIDS management in office practice. Antiretroviral therapy.
    Hartman AF
    Prim Care; 1997 Sep; 24(3):531-60. PubMed ID: 9271691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational approaches to resistance: nucleoside analogues.
    Mayers D
    AIDS; 1996 Nov; 10 Suppl 1():S9-13. PubMed ID: 8970670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.
    van der Ende ME; Prins JM; Brinkman K; Keuter M; Veenstra J; Danner SA; Niesters HG; Osterhaus AD; Schutten M
    AIDS; 2003 Jul; 17 Suppl 3():S55-61. PubMed ID: 14565610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approaches to treatment for HIV-1 infection.
    Powderly WG
    J Neurovirol; 2000 May; 6 Suppl 1():S8-S13. PubMed ID: 10871760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance.
    Campo RE; Rosa I; Lichtenberger PN; Suarez G; Rivera FA; Jayaweera DT; Rodriguez AE; Wahlay NA; Kolber MA
    AIDS Res Hum Retroviruses; 2003 Aug; 19(8):653-6. PubMed ID: 13678466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.
    Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M
    J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.